Loading...
NPI 1649928136 · Park Ridge, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Medlab Technologies LLC is a clinical medical laboratory provider located in Park Ridge, Illinois. This profile covers 5 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Medlab Technologies LLC |
| Address | 1480 Renaissance Dr Ste 212 |
| City | Park Ridge |
| State | IL |
| ZIP | 60068 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | March 14, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $7.3M |
| Medicaid | $87.6K |
MEDLAB TECHNOLOGIES LLC’s billing profile is overwhelmingly focused on COVID-19 testing and related specimen services, driven by codes that map to provision of self-administered tests and SARS-CoV-2 molecular and antigen testing. Its lifetime Medicare revenue is $7.3M and the top 3 Medicare codes by revenue account for 99.9% of that Medicare total, which points to a narrow service line concentrated on pandemic-era diagnostic products.
Revenue concentration on Medicare is extreme: K1034 accounts for $7.2M (99.8% of the provider’s Medicare revenue) and the precomputed top-three share is 99.9%, signaling that a single code dominates Medicare receipts and that routine lab panels or diversified testing lines are not material to this provider’s Medicare business. Such concentration creates high sensitivity in the provider’s Medicare revenue to coding or policy changes affecting K1034.
K1034’s national standing is exceptional: the provider reports 602.9K claims and $7.2M revenue for K1034 and it ranks #67 of 30143 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code). By contrast, the provider’s other Medicare codes are small contributors—U0003 (98 claims, $7.3K, ranks #458 of 973 nationally, 53th percentile) and 87811 (97 claims, $4K, ranks #749 of 10132 nationally, 92th percentile)—indicating dominance on the self-test code but otherwise modest participation on traditional molecular and immunoassay test codes.
On Medicaid the provider reports $87.6K lifetime revenue with its top three Medicaid codes accounting for 92.5% of that total, demonstrating a similarly concentrated payer-level mix though at far lower absolute dollars than Medicare. The Medicaid top codes are U0003 ($49.7K, 56.8% of Medicaid revenue), U0005 ($16.1K, 18.4%), and G2023 ($15.2K, 17.4%), which together indicate the Medicaid business is also driven by SARS‑CoV‑2 testing and specimen-collection services rather than broad clinical laboratory testing.
In-state competitive standing on Medicaid is middle-of-the-market for its core molecular test: U0003 ranks #157 of 350 providers in-state (55th percentile) and U0005 ranks #107 of 210 (49th percentile), which suggests typical, unremarkable participation in state Medicaid for these laboratory testing services rather than market leadership. The presence of G2023 and 87811 in the Medicaid top codes further confirms the operational focus on specimen collection and antigen/immunoassay testing rather than diversified clinical lab services.
Comparing payers, Medicare dominates this provider’s portfolio: Medicare revenue is $7.3M versus Medicaid revenue of $87.6K, making this effectively a Medicare-driven entity in scale. Analysts should treat the provider as functionally single-payer dominant for commercial Medicare-related reimbursement patterns, with Medicaid activity present but quantitatively minor.
The provider’s national rank and percentile language indicate both an outlier and routine aspects: K1034 is explicitly an “extreme outlier, far above typical national volume,” while several other codes are characterized as “typical, unremarkable volume” at their respective percentiles. This mix—one highly dominant outlier code plus several modest, typical-volume codes—signals a specialized operational model rather than broad-based laboratory services.
The NPI was enumerated on 2022-03-14 (~4 years ago), which implies this concentrated testing footprint developed within a relatively recent operational window. For competitive or contract discussions, that short tenure combined with high concentration in pandemic-era codes suggests rapid specialization that may respond quickly to reimbursement or coding policy changes impacting these specific codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 602,860 | $10 | $7.2M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 100 | $70 | $7.3K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 100 | $40 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 100 | $30 | $2.5K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 100 | $20 | $2.3K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 660 | $80 | $49.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 640 | $30 | $16.1K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 660 | $20 | $15.2K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 140 | $40 | $5.9K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 670 | $1 | $670 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 157 | 350 | 400 | $70 | $514.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 107 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 181 | 400 | 550 | $20 | $90.8K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 341 | 550 | 240 | $40 | $42.4K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 29 | 60 | 660 | $1 | $3.2K |
Other providers in the same ZIP code as Medlab Technologies LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| John Hamilton | IL | Anatomic Pathology & Clinical Pathology Physician | $6.4K | $11.7M |
| Michael Pins | IL | Specialist | $67.2K | $5.6M |
| Rahul Khapekar | IL | Family Medicine Physician | $5.2M | $410 |
| Advocate Health And Hospitals Corporation | IL | General Acute Care Hospital | $0 | $3.9M |
| William Menegas | IL | General Practice Dentistry | $0 | $3.4M |
| Cranial Technologies, Inc. | IL | Prosthetic/Orthotic Supplier | $0 | $3.1M |
| Rajendra Gogia | IL | Pain Medicine (Physical Medicine & Rehabilitation) Physician | $893.5K | $1.6M |
| Oliver Kim | IL | Anatomic Pathology & Clinical Pathology Physician | $98.6K | $2M |
| Andrea Blumstein | IL | Anatomic Pathology & Clinical Pathology Physician | $66.1K | $1.9M |
| City Of Park Ridge | IL | Land Ambulance | $463.9K | $1.1M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.